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There has been increasing interest in recent years in negative
regulators of haemopoietic stem cell proliferation. Such fac-
tors, as well as being of general interest in the understanding
of the regulation of haemopoiesis, may also have profound
clinical implications; for example, in alleviating the neutro-
penia which follows destruction of the haemopoietic system
by cytotoxic agents used in tumour therapy, or in the protec-
tion of stem cells in vitro during bone marrow purging prior
to autologous bone marrow transplantation.
One limitation to our current knowledge of the regulators
of haemopoietic stem cell proliferation is that the stem com-
partment is as yet ill defined and consists of a range of cell
types displaying varying degrees of self renewal or
differentiation potential (Schofield, 1978). The majority of
'stem cell' regulators have been defined on the basis of the
murine Colony Forming Unit-Spleen (CFU-S) assay or
equivalent in vitro assays, but it is becoming increasingly
clear that these assays do not detect the most primitive
haemopoietic stem cell. For efficient engraftment into
irradiated recipient mice, CFU-S are required for the early
transient phase and the 'Pre-CFU-S' compartment is required
for long-term repopulation (Jones et al., 1990). Therefore,
although the CFU-S (or equivalent) cell is not the most
primitive in the haemopoietic system, its self-renewal capacity
and multi-lineage potential serves as a valuable model system
for the evaluation of stem cell regulators. It remains to be
seen whether the stem cell inhibitor described below, and the
other factors affecting stem cell proliferation, are also capable
of altering the proliferative status of the pre-CFU-S cells.
The term 'Stem Cell', as used in this review, will refer to the
CFU-S cell unless otherwise stated.
In the normal bone marrow, only c.10% of the haemo-
poietic stem cells are actively proliferating, the remaining
cells being quiescent. When the murine haemopoietic system
is partially ablated, for example by chemotherapeutic agents
or irradiation, CFU-S cell proliferation is stimulated to
regenerate the haemopoietic system and up to 60% of the
CFU-S cells may then be actively proliferating. Once the
bone marrow is repopulated, the proliferative status of the
CFU-S cells return to normal.
It has been proposed, on the basis of these and other
observations, that both inhibitors and stimulators of haemo-
poietic stem cell proliferation must exist. Studies performed
over the past 20 years have identified a number of negative
regulators of haemopoietic stem cell proliferation. For the
purposes of this review, and as our own studies have been
dedicated to SCI/MIP-la, discussion of this cytokine will
dominate this review. Readers are referred to reviews by
Axelrad (1990) and Graham and Pragnell (1990) for discus-
sions on the other haemopoietic inhibitors.
SCI/MIP-loa and the inhibition ofstem cell proliferation
Studies by Lord, Wright and colleagues in the mid seventies
identified an activity in normal bone marrow extracts which
inhibited murine haemopoietic CFU-S cell proliferation
apparently by holding stem cells close to the G,/S phase
transition point (Lord et al., 1979; Wright et al., 1980, Lord
& Wright 1980). This stem cell inhibitor (SCI) was produced
by bone marrow derived macrophages, and was specific for
the stem cell compartment, having no inhibitory effects on
more mature progenitors.
We have recently developed an in vitro assay for a cell with
properties in common with the day 12 CFU-S cell (Pragnell
et al., 1988; Lorimore et al., 1990). This assay has been used
to characterise and purify an inhibitor of CFU-S prolifera-
tion (Graham et al., 1990) which we have called Stem Cell
Inhibitor (SCI).
Primary sequence analysis revealed that murine SCI is
identical to a previously described cytokine, Macrophage
Inflammatory Protein lx (Davatelis et al., 1988), a member
of a large family of related cytokines. This family is defined
on the basis of sequence homology and on the presence of
four cysteines which have been positionally conserved (for a
review see Wolpe & Cerami, 1989). A subset within this
family includes the basic cytokine MIP-2, Platelet Factor-4
(PF-4), P-thromboglobulin, Interleukin-8 and melanoma
growth stimulatory activity (MGSA) proteins. MIP-2 and
PF4 are chemotactic for polymorphonuclear cells (see Wolpe
& Cerami, 1989).
SCI/MIP-la is a small heparin binding peptide with a
molecular weight of 8 kD although the molecule readily
forms large non covalent aggregates with molecular weights
in excess of one million daltons. Intriguingly, a related pep-
tide (70% homologous at the amino acid level), MIP-1lB
(Wolpe & Cerami, 1989), which copurified with MIP-lo dis-
plays no inhibitory activity at the concentrations tested
(Graham et al., 1990). More recent reports suggest that
SCI/MIP-la, MIP-1p and MIP-2 can stimulate progenitor
cell proliferation, but only in conditions where growth factor
concentrations are limiting in in vitro progenitor assays
(Broxmeyer et al., 1990).
The human SCI/MIP-lo homologue is also a peptide with
a molecular weight of approximately 8 kD and forms large
self aggregates. It is equally effective as a CFU-S prolifera-
tion inhibitor and we are currently using the human SCI/
MIP-lo in preclinical trials designed to test its efficacy in
reducing myelotoxicity during drug treatment of mice.
The inhibitory activities ofSCI/MIP-lx are not confined to
the haemopoietic system. We have shown both human and
murine SCI/MIP-Ia to be active in inhibiting clonogenic
epidermal cells (Parkinson & Graham, unpublished results),
although it is not yet clear whether this is a direct or indirect
effect on the primary epidermal cells. The source of SCI/
MIP-1x in vivo in the skin remains to be determined, how-
ever, two possibilities are being considered. In the normal
mouse skin epidermal proliferation unit (EPU), a Langerhans
cell, which is of monocytic/lymphoid origin and expresses
SCI/MIP-la, is in close proximity to the slow cycling epider-
mal keratinocyte and may be involved in establishing the
proliferative hierarchy observed. Alternatively, during skin
wounding and/or inflammation, local infiltration of macro-
phages and T-cells may produce SCI/MIP-1o although the
functional implications of such production would have to be
investigated. The availability of probes allowing in situ or
immunocytochemical analysis should allow us to investigate
these possibilities further.
SCI/MIP-la gene structure
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The mouse MIP-loa protein was originally purified from
endotoxin stimulated macrophages and sequenced. This led
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to the isolation of a cDNA alone (Davatelis et al., 1988) and
subsequent isolation and sequence of a single encoding gene
(Grove et al., 1990). At least three independent groups have
cloned human cDNA's which have turned out to be homo-
logous to human SCI/MIP-lo: Obaru et al. (1986) cloned the
LD78 cDNA using differential hybridisation of tumour pro-
moter stimulated human tonsillar lymphocytes; Zipfel et al.
(1989) cloned the cDNA (pAT464) from mitogen stimulated
peripheral blood T cells; and Forsdyke (1985) cloned the
cDNA (GOS19-1) from lectin stimulated cultured blood
mononuclear cells.
Southern blot analyses of EcoRl digested human DNAs
probed with LD78, or pAT464 cDNA sequences revealed
1-3 bands depending on the DNA source (Irving et al.,
1990, Nakao et al., 1990). Three groups have indendently
cloned at least three human SCI/MIP-1a-related genes, at
least two of which are linked: LD78a/pAT464.1/GOS19-1
and LD78P/pAT 744.1/GOS19-2 (Nakao et al., 1990; Irving
et al., 1990; Blum et al., 1990). The pAT464.1 and
pAT 744.1 genes are separated by 14 kbp and are transcribed
from opposite strands of DNA. This suggests that the two
genes recently arose by gene duplication and divergence
which included the insertion of an Alul repetitive sequence
into the 5' flanking sequence of the GOS19-2/LD78P gene
(Nakao et al., 1990; Blum et al., 1990). A third member of
the family has been identified, LD78y, pAT 464.2 and
GOS19-3 (Nakao et al., 1990; Blum et al., 1990; Irving et al.,
1990), as has a putative human MIP-1p cDNA homologue
(Act-2, Lipes et al., 1988) but these have yet to be fully
characterised.
The mouse SCI/MIP-la and the related TCA-3 and MIP-
IP genes are clustered on chromosome 11 within 5 cM of the
p53 (proximal) and Hox-2 (distal) loci. In humans, SCI/MIP-
la (LD78) and the related Act-2 and JE genes are clustered
on chromosome 17 (ql1-121) (Irving et al., 1990). However,
although the murine MIP-2 gene also maps to chromosome
11, members of the human MIP-2 gene family (PF4 and
MGSA), map to chromosome 4(ql3-q21) (Wolpe & Cerami,
1989).
The human SCI/MIP-la gene maps near to sites of genetic
lesions (17qll-q21) associated with a number of disorders.
For example, (a) the acute promyelocytic leukaemia (APL)
t(15:17) (q22,ql2-2) translocation, involves a specific break-
point (17q21.1) at the retinoic acid receptor-a gene (de The et
al., 1990); (b) von Recklinghausen neurofibromatosis (NFI),
an autosomal dominant disease, where the NFl gene encodes
a protein containing ras GTPase activity (Xu et al., 1990);
and (c) a loss of heterozygosity (LOH) in breast cancer
(Cropp et al., 1990). Although it is unlikely that the
SCI/MIP-la gene is itself directly involved in the cellular
transformation process, nearby genetic lesions which activate
proto-oncogenes or inactive suppressor genes may also coin-
cidentally lead to aberrant SCI/MIP-la gene expression. The
up-regulation of SCI/MIP-Ia gene expression has been de-
tected in the peripheral blood of a number of ANLL and
ALL patients (Yamamura et al., 1989) and in haemopoietic
cells derived from patients with aplastic anaemia and myelo-
dysplastic syndrome (N.S. Young, personal communication).
It would be interesting to determine whether aberrant SCI/
MIP-la protein expression contributes to the suppression of
normal haemopoiesis in these patients, and whether the SCI/
MIP-la gene locus on chromosome 17 has been disturbed in
these neoplasias.
SCI/IMP-la gene expression
SCI/MIP-lazprotein was first described as a haemopoietic
stem cell inhibitor activity in bone marrow extracts (Lord &
Wright, 1980) and monocytes (Pojda et al., 1988), and SCI/ MIP-laz mRNA is barely detectable in normal bone marrow, but is readily detectable in cultured bone marrow macro-
phages (A. Reid unpublished results). More recent studies
indicate that SCI/MIP-lac gene expression is only detectable
in a limited number of haemopoietic cell lineages
- macro-
phages (Davatelis et al., 1988; Wolpe & Cerami 1989; Obaru
et al., 1986, Yamamura et al., 1989), epidermal Langerhans
cells (K. Parkinson unpublished results), activated T-cells
(Yamamura et al., 1989) and mast cells (Gordon et al., 1990).
One report describes the detection of SCI/MIP-la gene trans-
cripts in phorbol ester treated primary cultured human
fibroblasts and a human glioma cell line (U1O5MG) (Nakao
et al., 1990), but it is unclear whether this represents cross-
hybridisation of the human LD78 probe to transcripts from a
related member of the MIP multigene family. Structural
analysis of the nuclear murine SCI/MIP-la gene in fibroblast
and epithelial cell lines suggest the gene is in an inactive
conformation, consistent with the inability to detect SCI/
MIP-la mRNA by Northern blot or Polymerase Chain
Reaction (PCR) analyses (M.P. unpublished results).
In addition to the apparent tissue-specificity of SCI/MIP-
la gene expression, the molecular mechanism(s) regulating its
expression are beginning to be elucidated. Published and
unpublished data from this and other laboratories, and a
comparison with analyses of other cytokines involved in
haemopoiesis and the immune response, indicate that SCI/
MIP-la gene expression is regulated at the levels oftranscrip-
tion, mRNA stability, mRNA processing and translation.
For example, sequence analysis of the murine (Davatelis et
al., 1988) and human (Forsdyke, 1985; Obaru et al., 1986;
Zipfel et al., 1989) SCI/MIP-lI cDNAs revealed a number of
conserved (TATTT) motifs in the 3' untranslated region of
the mRNA which have been implicated in the modulation of
mRNA stability of a number of other cytokine mRNAs
(Caput et al., 1986; Shaw & Kamen, 1986). Similarly, as
mentioned above, SCI/MIP-lI mRNA is super-induced dur-
ing endotoxin (lipopolysacharride, LPS) stimulation of
murine macrophages (Davatelis et al., 1988), and is super-in-
duced in human T-cell lines by phorbol esters (PMA) and/or
PHA and cyclohexamide (Obaru et al., 1986; Yamamura et
al., 1989; Blum et al., 1990). Interestingly, a basal level of
SCI/MIP-lac mRNA is detected in unstimulated cultured
murine macrophage (Graham et al., 1990; Davatelis et al.,
1988) and mast cell lines (Gordon et al., 1990, and M.P.
unpublished results), whereas it is undetectable in unstim-
ulated human monocyte (U937) and T-cell (Jurkat) lines
although it can be induced by PHA and/or PMA (Obaru et
al., 1986; Yamamura et al., 1989; Blum et al., 1990).
Sequence comparison of the proximal promoters of the
human and mouse SCI/MIP-lac genes with those of other
cytokine genes such as GM-CSF, have revealed a number of
conserved potential transcription factor binding sites. These
include potential NF-icB (related to the c-Rel proto-oncogene
(Ballard et al., 1990)), NF-GMa (which may be related to the
NF-KB family of proteins, (Shannon et al., 1990)), API
(encoded by the c-fos and c-jun proto-oncogenes, for review
see Abate & Curran, 1990) and PU1 (a member of the c-ets
family of proto-oncogenes (Klemsz et al., 1990)) binding
sites. These transcription factors are all nuclear proto-onco-
genes which have been implicated in the early response to
mitogenic stimulii (e.g. phorbol esters and AP1) and in cell
proliferation. This implies that SCI-MIP-la gene transcrip-
tion is regulated as a function of cell proliferation/activation,
and as it is a negative regulator of stem cell proliferation it is
tempting to speculate that one role of SCI/MIP-ia, partic-
ularly that produced by macrophages in the bone marrow, is
as a classical negative feedback factor. Furthermore, it raises
the possibility that the activation of the nuclear proto-
oncogene(s) in certain neoplasias may lead to aberrant SCI/
MIP-hi gene expression.
Concluding remarks
It is clear that SCI/MIP-lagene expression is specific to a
limited number of haemopoietic cells, is regulated at both
transcriptional and post-transcriptional levels, and may also
be regulated at the translational and post-translational levels.
There is ample evidence to suggest that the control of
haemopoietic stem cell proliferation occurs at the level of the992 M. PLUMB et al.
stromal micro-environment. It is therefore necessary to exam-
ine the localisation of SCI/MIP-la protein in the bone mar-
row extra-ellular matrix as it is clearly synthesised and
released by normal bone marrow cells, including macro-
phages. One obvious approach is to utilise in situ hybridisa-
tion and immunocytochemical techniques, although to date it
has proven very difficult to demonstrate the presence of
either peptide or mRNA transcripts of other known cyto-
kines in normal bone marrow or longer-term marrow cul-
tures. If SCI/MIP-la is also expressed during embryogenesis
it is as yet undetectable by in situ hybridisation analyses (N.
Hastie, personal communication), in contrast to TGF-P
which is readily detectable in embryonic tissue.
Another approach to elucidate the physiological relevance
of a cytokine is by gene inactivation using homologous
recombination. However, as SCI/MIP-la is part of a multi-
gene family and there appears to be a redundancy of func-
tion between various haemopoietic growth factors, single
gene inactivation may not be particularly informative, and
cross-breeding of mice with a range of inactivated genes may
well provide an exciting approach to the problem. Alterna-
tively, studies on the tissue distribution of the SCI/MIP-la
receptor would provide invaluable information on the phys-
iological role of the cytokine, but the biochemical properties
of the purified peptide is currently hampering progress in
binding studies.
The clinical potential of SCI/MIP-la is obvious. We now
have evidence that inoculation of mice with SCI/MIP-li in
vivo leads to a dose dependent reduction in the cycling status
of CFU-S/CFU-A cells (D. Dunlop, personal communica-
tion). Experiments are now underway in a number of lab-
oratories to evaluate various therapeutic drug protocols.
The possibility that SCI/MIP-la contributes to the sup-
pression of stem cell proliferation in certain neoplasias re-
mains to be explored. In parallel, it would be of significant
interest if aberrant SCI/MIP-la gene expression could be
linked to specific chromosomal translocations or the activa-
tion of certain nuclear proto-oncogene(s). Thus, whilst there
are a number of intriguing observations concerning SCI/
MIP-la, a number of detailed studies are required before a
clear picture of its physiological role will emerge.
The authors work was supported by a grant to the Beatson Institute
from the Cancer Research Campaign.
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